Clinical Scorecard: Association between Cancer Predisposition Genes and the Risk of Lymphoid Malignancies
At a Glance
Category
Detail
Condition
Lymphoid malignancies (LM), including over 100 subtypes such as DLBCL, FL, MCL, MZL, SLL, TCL, HL, WM, and MM
Key Mechanisms
Inherited pathogenic variants (PVs) in cancer predisposition genes, especially those involved in DNA damage repair, may increase LM risk; family history is a significant risk factor
Target Population
Adults aged 18 years or older diagnosed with lymphoid malignancies or controls without hematologic malignancies
Care Setting
Specialized oncology and hematology clinics, genetic testing centers, and research cohorts
Key Highlights
LM are heterogeneous neoplasms with diverse subtypes and biological behaviors.
Family history of hematologic cancer is a strong risk factor, with subtype-specific familial risks exceeding 4-fold in some LM subtypes.
Pathogenic variants in known cancer predisposition genes (e.g., BRCA1/2, ATM, TP53) may contribute to LM risk, but large-scale studies are needed for definitive associations.
Guideline-Based Recommendations
Diagnosis
Central pathology review and WHO classification for accurate LM subtype diagnosis.
Genetic testing for PVs in cancer predisposition genes may be considered in patients with family history or early-onset LM.
Management
Incorporate genetic findings into individualized therapy decisions and familial risk counseling.
Use established criteria (e.g., NCCN) to guide genetic testing eligibility based on cancer subtype, age, and family history.
Monitoring & Follow-up
Surveillance for secondary malignancies in patients with known PVs in cancer predisposition genes.
Regular assessment of family members at risk based on genetic findings.
Risks
Increased risk of LM associated with PVs in DNA damage repair genes and familial clustering.
Potential for overlapping risk across different LM subtypes within families.
Patient & Prescribing Data
Adults with newly diagnosed LM and controls from a large clinic-based cohort.
Genetic testing results can inform targeted therapies and risk management strategies for patients and their relatives.
Clinical Best Practices
Obtain detailed family history of hematologic malignancies during patient evaluation.
Consider germline genetic testing for cancer predisposition genes in LM patients meeting clinical criteria.
Use high-quality DNA sequencing and standardized variant annotation for accurate PV identification.
Integrate genetic findings with clinical and pathological data to guide personalized management.
Educate patients and families about the implications of genetic risk and surveillance options.
by Nicholas J. Boddicker, Raphael Mwangi, Dennis P. Robinson, Cristine Allmer, Allison C. Rosenthal, Thomas M. Habermann, Andrew L. Feldman, Lisa M. Rimsza, Rebecca L. King, Melissa C. Larson, Bri J. Negaard, Aaron D. Norman, Nikhil Rajkumar, Stephen M. Ansell, Angela Dispenzieri, David L. Murray, Vincent Rajkumar, Shaji Kumar, Jithma P. Abeykoon, Grzegorz S. Nowakowski, Thomas E. Witzig, Anne J. Novak, Susan L. Slager, Celine M. Vachon, James R. Cerhan
Novo Nordisk’s Parkinson’s cell therapy finds a new home at Cellular Intelligence, while base editing, prime editing, and large-insertion genome writing push forward
